These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 17804128)

  • 1. Transfusion-related immunomodulation (TRIM): an update.
    Vamvakas EC; Blajchman MA
    Blood Rev; 2007 Nov; 21(6):327-48. PubMed ID: 17804128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumonia as a complication of blood product transfusion in the critically ill: transfusion-related immunomodulation (TRIM).
    Vamvakas EC
    Crit Care Med; 2006 May; 34(5 Suppl):S151-9. PubMed ID: 16617260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible mechanisms of allogeneic blood transfusion-associated postoperative infection.
    Vamvakas EC
    Transfus Med Rev; 2002 Apr; 16(2):144-60. PubMed ID: 11941576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. White-blood-cell-containing allogeneic blood transfusion and postoperative infection or mortality: an updated meta-analysis.
    Vamvakas EC
    Vox Sang; 2007 Apr; 92(3):224-32. PubMed ID: 17348871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meta-analysis of randomized controlled trials investigating the risk of postoperative infection in association with white blood cell-containing allogeneic blood transfusion: the effects of the type of transfused red blood cell product and surgical setting.
    Vamvakas EC
    Transfus Med Rev; 2002 Oct; 16(4):304-14. PubMed ID: 12415516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Meta-analysis of randomized controlled trials comparing the risk of postoperative infection between recipients of allogeneic and autologous blood transfusion.
    Vamvakas EC
    Vox Sang; 2002 Nov; 83(4):339-46. PubMed ID: 12437521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppressive effects of allogeneic blood transfusions: implications for the patient with a malignancy.
    Bordin JO; Blajchman MA
    Hematol Oncol Clin North Am; 1995 Feb; 9(1):205-18. PubMed ID: 7737942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How much residual plasma may cause TRALI?
    Win N; Chapman CE; Bowles KM; Green A; Bradley S; Edmondson D; Wallis JP
    Transfus Med; 2008 Oct; 18(5):276-80. PubMed ID: 18937733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukodepletion of autologous whole blood has no impact on perioperative infection rate and length of hospital stay.
    Frietsch T; Karger R; Schöler M; Huber D; Bruckner T; Kretschmer V; Schmidt S; Leidinger W; Weiler-Lorentz A
    Transfusion; 2008 Oct; 48(10):2133-42. PubMed ID: 18564391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transfusion-related immunomodulation by platelets is dependent on their expression of MHC Class I molecules and is independent of white cells.
    Aslam R; Speck ER; Kim M; Freedman J; Semple JW
    Transfusion; 2008 Sep; 48(9):1778-86. PubMed ID: 18522705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transfusion-related immunomodulation: a second hit in an inflammatory cascade?
    Bilgin YM; Brand A
    Vox Sang; 2008 Nov; 95(4):261-71. PubMed ID: 19138255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion immunomodulation or TRIM: what does it mean clinically?
    Blajchman MA
    Hematology; 2005; 10 Suppl 1():208-14. PubMed ID: 16188675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfusion related acute lung injury (TRALI) caused by red blood cell transfusion involving residual plasma anti-HLA antibodies: a report on two cases and general considerations.
    Odent-Malaure H; Quainon F; Ruyer-Dumontier P; Ducroz S; Verdier P; Voitellier E; Raynal MF; Fromont P; Muller JY; Rebibo D; Absi L; Garraud O
    Clin Dev Immunol; 2005 Dec; 12(4):243-8. PubMed ID: 16584109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of transfusion-associated immunosuppression.
    Blajchman MA; Bordin JO
    Curr Opin Hematol; 1994 Nov; 1(6):457-61. PubMed ID: 9371323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why have meta-analyses of randomized controlled trials of the association between non-white-blood-cell-reduced allogeneic blood transfusion and postoperative infection produced discordant results?
    Vamvakas EC
    Vox Sang; 2007 Oct; 93(3):196-207. PubMed ID: 17845256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulation and blood transfusion.
    Blajchman MA
    Am J Ther; 2002; 9(5):389-95. PubMed ID: 12237730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical effects of leucoreduction of blood transfusions.
    Bilgin YM; van de Watering LM; Brand A
    Neth J Med; 2011 Oct; 69(10):441-50. PubMed ID: 22058263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory effects of blood transfusions: the synergic role of soluble HLA Class I free heavy-chain molecules detectable in blood components.
    Ghio M; Contini P; Ubezio G; Mazzei C; Puppo F; Indiveri F
    Transfusion; 2008 Aug; 48(8):1591-7. PubMed ID: 18466172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transfusion-related immunomodulation due to peripheral blood dendritic cells expressing the CD200 tolerance signaling molecule and alloantigen.
    Clark DA; Gorczynski RM; Blajchman MA
    Transfusion; 2008 May; 48(5):814-21. PubMed ID: 18298594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research advance on transfusion-related immunomodulation].
    Zhu XF; Xia R
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Feb; 18(1):268-72. PubMed ID: 20137161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.